Overview

Nilotinib in the Treatment of Systemic Sclerosis

Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
A phase IIa open-label single center pilot study to assess the safety and efficacy of Nilotinib in patients with Scleroderma.
Phase:
Phase 2
Details
Lead Sponsor:
Hospital for Special Surgery, New York
Collaborators:
Novartis Pharmaceuticals
Rudolph Rupert Scleroderma Program